InvestorsHub Logo
Followers 20
Posts 1631
Boards Moderated 0
Alias Born 11/10/2010

Re: randychub post# 232

Thursday, 08/24/2017 9:43:48 AM

Thursday, August 24, 2017 9:43:48 AM

Post# of 7108
JMP Securities initiates coverage on Revance Therapeutic (NASDAQ: RVNC) with a Market Outperform rating and a price target of $34.00.

Analyst Donald Ellis believes both the therapeutic and aesthetic applications of the company's products with have cost and quality-of-life benefits for patients. The analyst says the stock is on the cusp of a valuation growth stage citing multiple NT catalysts, clinical read-outs, BLA filings and a first indication reaching the market around 2019/2020.

For an analyst ratings summary and ratings history on Revance Therapeutic click here. For more ratings news on Revance Therapeutic click here.

Shares of Revance Therapeutic closed at $22.70 yesterday.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News